A screenshot from Henlius Biotech’s official website. [Image/henlius.com] Hong Kong-listed Shanghai Henlius Biotech Inc announced on Friday that the company’s business partner, Accord BioPharma Inc, has received approval from the United States Food and Drug Administration for HERCESSI™, a trastuzumab biosimilar self-developed and manufactured by the Shanghai biopharmaceutical company. The approval made the therapy the … Continue reading Accord BioPharma has receives approval for HERCESSI